{"id":"oros-methylphenidate","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness/anxiety"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"2-5","effect":"Tachycardia"},{"rate":"2-5","effect":"Elevated blood pressure"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:31:13.731379","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their concentration in the synaptic cleft. The OROS (osmotic release oral system) formulation provides extended-release delivery over 12 hours, maintaining therapeutic levels throughout the day. This mechanism enhances focus, attention, and impulse control in patients with attention deficit hyperactivity disorder.","oneSentence":"OROS methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain to improve attention and reduce hyperactivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:05.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention deficit hyperactivity disorder (ADHD) in children and adults"}]},"_fixedFields":["pubmed(161)"],"trialDetails":[{"nctId":"NCT05842330","phase":"PHASE3","title":"Benefits of ADHD Treatment in Detained People","status":"RECRUITING","sponsor":"Stéphanie Baggio","startDate":"2024-01-01","conditions":"ADHD","enrollment":150},{"nctId":"NCT02293655","phase":"PHASE4","title":"The Effects of ADHD Medication (TEAM) Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-01-12","conditions":"ADHD","enrollment":204},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT05410626","phase":"NA","title":"The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-06-01","conditions":"Adhd","enrollment":78},{"nctId":"NCT00916786","phase":"","title":"Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":240},{"nctId":"NCT00763971","phase":"PHASE3","title":"Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2008-11-17","conditions":"ADHD","enrollment":336},{"nctId":"NCT01552902","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-03","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":549},{"nctId":"NCT01552915","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-17","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":464},{"nctId":"NCT01727414","phase":"PHASE4","title":"Attention Deficit Disorder Medication Response Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2006-06","conditions":"ADHD - Inattentive Type, ADHD - Combined Type","enrollment":171},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT00516269","phase":"PHASE3","title":"Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-08","conditions":"Breast Cancer, Fatigue, Gastrointestinal Cancer","enrollment":42},{"nctId":"NCT01853280","phase":"PHASE2, PHASE3","title":"L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":47},{"nctId":"NCT01109849","phase":"PHASE3","title":"Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth","status":"COMPLETED","sponsor":"Florida International University","startDate":"2010-11","conditions":"ADHD, Growth","enrollment":230},{"nctId":"NCT00603434","phase":"PHASE1","title":"Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-01","conditions":"Methamphetamine Dependence, Methamphetamine Abuse","enrollment":16},{"nctId":"NCT00302458","phase":"PHASE4","title":"A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT00550147","phase":"PHASE2","title":"Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2004-02","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":30},{"nctId":"NCT02352051","phase":"PHASE4","title":"Effects of Atx and Oros-mph on Executive Functions","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-02","conditions":"Executive Dysfunction","enrollment":43},{"nctId":"NCT01933880","phase":"PHASE4","title":"A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2009-12","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":194},{"nctId":"NCT02215538","phase":"PHASE2, PHASE3","title":"OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":47},{"nctId":"NCT00714688","phase":"PHASE3","title":"A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2008-02","conditions":"Attention Deficit/ Hyperactivity Disorder","enrollment":279},{"nctId":"NCT00307684","phase":"PHASE3","title":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2006-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":155},{"nctId":"NCT00758160","phase":"PHASE4","title":"The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":296},{"nctId":"NCT01533493","phase":"NA","title":"Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)","enrollment":33},{"nctId":"NCT01012622","phase":"PHASE4","title":"An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":142},{"nctId":"NCT00302393","phase":"PHASE3","title":"Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00889915","phase":"PHASE4","title":"Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":228},{"nctId":"NCT01060150","phase":"PHASE4","title":"An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":115},{"nctId":"NCT00323947","phase":"PHASE4","title":"Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2003-05","conditions":"Attention Deficit Disorder With Hyperactivity, Epilepsy","enrollment":33},{"nctId":"NCT00937040","phase":"PHASE4","title":"Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2009-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":357},{"nctId":"NCT00264797","phase":"PHASE3","title":"Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-02","conditions":"ADHD, Substance Abuse","enrollment":303},{"nctId":"NCT00181714","phase":"PHASE4","title":"Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-11","conditions":"ADHD","enrollment":203},{"nctId":"NCT00880217","phase":"PHASE2","title":"A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":430},{"nctId":"NCT01127646","phase":"PHASE4","title":"A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00585910","phase":"PHASE4","title":"Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-01","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":94},{"nctId":"NCT00253747","phase":"PHASE3","title":"Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2005-11","conditions":"ADHD, Smoking","enrollment":255},{"nctId":"NCT00593112","phase":"PHASE4","title":"Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-11","conditions":"ADHD","enrollment":39},{"nctId":"NCT00931398","phase":"PHASE4","title":"Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2010-04","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":""},{"nctId":"NCT00778310","phase":"PHASE4","title":"Neuroimaging of the Effects of Concerta in the Treatment of ADHD","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2008-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":76},{"nctId":"NCT00598182","phase":"","title":"Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":64},{"nctId":"NCT00246207","phase":"PHASE3","title":"CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2005-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":32},{"nctId":"NCT00530257","phase":"PHASE4","title":"Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30},{"nctId":"NCT00757029","phase":"PHASE4","title":"Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-10","conditions":"Attention Deficit Disorder With Hyperactivity, Methylphenidate, Pharmacogenetics","enrollment":150},{"nctId":"NCT01065259","phase":"PHASE4","title":"Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":262},{"nctId":"NCT00302354","phase":"PHASE4","title":"A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT00302367","phase":"PHASE4","title":"An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-01","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT00302406","phase":"PHASE4","title":"Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":50},{"nctId":"NCT00301639","phase":"PHASE3","title":"A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-03","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT00269776","phase":"PHASE3","title":"An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1998-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269815","phase":"PHASE3","title":"Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269802","phase":"PHASE3","title":"A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00269789","phase":"PHASE3","title":"A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1998-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT00246220","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2005-03","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":402},{"nctId":"NCT00304681","phase":"PHASE3","title":"An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":147},{"nctId":"NCT00549640","phase":"PHASE2","title":"Testing Methylphenidate for Smoking Abstinence","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-01","conditions":"Smoking","enrollment":80},{"nctId":"NCT01130467","phase":"","title":"Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-09","conditions":"Attention Deficit Disorders With Hyperactivity, Attention Deficit Disorder, Hyperkinetic Syndrome","enrollment":150},{"nctId":"NCT00482313","phase":"PHASE3","title":"Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Psychiatry Karolinska","startDate":"2007-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30},{"nctId":"NCT00518232","phase":"PHASE4","title":"A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2006-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":520},{"nctId":"NCT00862108","phase":"PHASE4","title":"Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2008-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":50},{"nctId":"NCT00842127","phase":"PHASE4","title":"Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)","status":"COMPLETED","sponsor":"Bundang CHA Hospital","startDate":"2006-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":150},{"nctId":"NCT00663442","phase":"PHASE4","title":"Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"1999-12","conditions":"ADHD","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":161,"recentPublications":[{"date":"2025 Nov","pmid":"40799022","title":"Pharmacokinetics and Bioequivalence of a Novel Extended-Release Formulation of Methylphenidate Hydrochloride for Attention-Deficit/Hyperactivity Disorder.","journal":"Clinical pharmacology in drug development"},{"date":"2026 Jan 5","pmid":"40707201","title":"A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time.","journal":"Fukushima journal of medical science"},{"date":"2025 Jun 3","pmid":"40493907","title":"Complex ADHD in a Child With Tic Disorder.","journal":"Journal of developmental and behavioral pediatrics : JDBP"},{"date":"2024 Nov","pmid":"39508643","title":"A Remedy for Crime? A Systematic Review on the Effects of Pharmacological ADHD Treatment on Criminal Recidivism and Rehabilitation in Inmates With ADHD.","journal":"Brain and behavior"},{"date":"2024 Jan 4","pmid":"38178233","title":"Protocol of a monocentric, double-blind, randomized, superiority, controlled trial evaluating the effect of in-prison OROS-methylphenidate vs. placebo treatment in detained people with attention-deficit hyperactivity disorder (BATIR).","journal":"Trials"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["concerta","Concerta"],"phase":"marketed","status":"active","brandName":"OROS methylphenidate","genericName":"OROS methylphenidate","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OROS methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain to improve attention and reduce hyperactivity. Used for Attention deficit hyperactivity disorder (ADHD) in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}